Hydrochloric Acid

Hydrochloric Acid

SCHEMBL6547743

CNC1CCc2c(ccc(O)c2O)C1.Cl

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 5/20 0.50
DRD4 known ✓ P21917 2/20 0.50
DRD3 known ✓ P35462 2/20 0.50
DRD1 known ✓ P21728 2/20 0.50
ADRA1D known ✓ P25100 2/20 0.45
ADRA1A known ✓ P35348 2/20 0.45
ADRA1B known ✓ P35368 2/20 0.45
ADRA2A known ✓ P08913 1/20 0.45
ADRA2B known ✓ P18089 1/20 0.45
ADRA2C known ✓ P18825 1/20 0.45
CA2 known ✓ P00918 2/20 0.44
ACHE known ✓ P22303 2/20 0.44
ADRB2 known ✓ P07550 2/20 0.39
CA1 P00915 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3829971 0.98 DRD2 (0.51) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL6843823 0.98 DRD2 (0.51) DRD2DRD4DRD3DRD1ADRA1D
Bromide SCHEMBL7037393 0.97 DRD2 (0.50) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL2956868 0.83 ADRA1D (0.49) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL11520474 0.81 DRD2 (0.57) DRD2DRD4DRD3DRD1ADRA1D
Bromide SCHEMBL6008428 0.80 DRD2 (0.50) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL7424155 0.79 DRD2 (0.71) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL7424159 0.79 DRD2 (0.71) DRD2DRD4DRD3DRD1ADRA1D
SCHEMBL14360233 0.79 DRD2 (0.67) DRD2DRD4DRD3DRD1CA1
Bromide SCHEMBL7336392 0.78 DRD2 (0.69) DRD2DRD4DRD3DRD1ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004013083-A1 NOLOMIROLE HYDROCHLORIDE FORM I CHIESI FARMACEUTICI S. P. A. (IT) 2004-02-12 WO claimed
EP-1384708-A1 Process for the manufacture of form I of nolomirole hydrochloride CHIESI FARMACEUTICI S.p.A. (IT) 2004-01-28 EP claimed
US-20040102652-A1 Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them CHIESI FARMACEUTICI S.P.A. (IT) 2004-05-27 US disclosed
EP-1384708-A1 Process for the manufacture of form I of nolomirole hydrochloride CHIESI FARMACEUTICI S.p.A. (IT) 2004-01-28 EP disclosed
EP-0788472-B1 A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES CHIESI FARMA SPA (IT) 2000-08-02 EP disclosed
US-6034277-A Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives CHIESI FARMACEUTICI S.P.A. (IT) 2000-03-07 US disclosed
US-5936125-A Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives CHIESI FARMACEUTICI S.P.A. (IT) 1999-08-10 US disclosed
US-5710336-A Process for the preparation of 5-6-dihydroxy-2-amino-1, 2, 3, 4-tetrahydronaphthalene derivatives CHIESI FARMACEUTICI S.P.A. (IT) 1998-01-20 US disclosed
EP-0788472-A1 A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES CHIESI FARMACEUTICI S.p.A. (IT) 1997-08-13 EP disclosed
WO-1995029147-A1 A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 1995-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102652-A1 Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them AADAT, AASDHPPT, AAAS DRD2 594/4885DRD4 857/4885DRD3 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.